Dong Liang

Shenyang Medical College — China

Medicine · Health Sciences

42h-index8.8kcitations292works1.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(29), Cancer-related molecular mechanisms research(25), Metabolomics and Mass Spectrometry Studies(24), Chronic Obstructive Pulmonary Disease (COPD) Research(18), Heme Oxygenase-1 and Carbon Monoxide(18)

Publications286 total

Preclinical Development of GT-14, a Novel Inhibitor of Gαi2 Protein: Comprehensive Evaluation of Physicochemical, Metabolic Characteristics and Tissue Distribution
The AAPS Journal·2025Open Access
Supplementary Data from Treatment Strategies and Mechanisms Associated with the Prevention of NASH-Associated HCC by a Toll-like Receptor 4 Inhibitor
2025Open Access
Supplementary Figure from Treatment Strategies and Mechanisms Associated with the Prevention of NASH-Associated HCC by a Toll-like Receptor 4 Inhibitor
2025Open Access
Supplementary Figure S1 from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer
2025Open Access
Supplementary Table S2 from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer
2025Open Access
Supplementary Table S1 from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer
2025Open Access
Supplementary Data from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer
2025Open Access
Supplementary Figure S3 from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer
2025Open Access
Supplementary Figure S4 from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer
2025Open Access
Supplementary Data from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer
2025Open Access
Supplementary table S4 from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer
2025Open Access
Supplementary Figure S2 from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer
2025Open Access
Supplementary table S3 from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer
2025Open Access
Drug Metabolism and Pharmacokinetic Evaluation of a Novel RNase H2 Inhibitor for the Treatment of Triple-Negative Breast Cancer
Pharmaceutics·2025· 2 citedOpen Access
From iPSCs to myotubes: Identifying potential biomarkers for human FSHD by single‐cell transcriptomics
Clinical and Translational Medicine·2025Open Access
Clay Attenuates Diarrhea Induced by Fat in a Mouse Model.
PubMed·2025Open Access
Characterizations of lung cancer microbiome and exploration of potential microbial risk factors for lung cancer
Scientific Reports·2025· 4 citedOpen Access
The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer
Molecular Cancer Therapeutics·2025· 4 citedOpen Access
Attitudes and Barriers Toward Antiretroviral Therapeutic Drug Monitoring Among Infectious Disease Providers
Medicina·2025Open Access
Biopharmaceutical Factors Involved in the Disposition of Mycophenolic Acid: A Comprehensive Review of ADME Properties and Their Potential Impact on Mycophenolic Acid Plasma Exposure
Current Drug Metabolism·2025
page 1 of 15Next →

Frequent Co-authors

Xifeng Wu(14), Jonathan P. Tyrer(11), Michelle A.T. Hildebrandt(11), Louise A. Brinton(10), Angela Brooks‐Wilson(10), Daniel W. Cramer(10), Julie M. Cunningham(10), Diana Eccles(10), Graham G. Giles(10), Marc T. Goodman(10), Estrid Høgdall(10), Allan Jensen(10), Lambertus A. Kiemeney(10), Diether Lambrechts(10), Douglas A. Levine(10), Jolanta Lissowska(10), Jan Lubiński(10), Chun Li(10), Hoda Anton‐Culver(9), Elisa V. Bandera(9)